Eulav Asset Management Madrigal Pharmaceuticals, Inc. Transaction History
Eulav Asset Management
- $4.11 Billion
- Q3 2024
A detailed history of Eulav Asset Management transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Eulav Asset Management holds 10,000 shares of MDGL stock, worth $2.93 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$2.93 Million
Previous $2.8 Million
24.24%
% of portfolio
0.05%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$727 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$599 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$595 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$585 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$579 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.02B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...